
Fate Therapeutics (FATE) Stock Forecast & Price Target
Fate Therapeutics (FATE) Analyst Ratings
Bulls say
Fate Therapeutics is estimated to have a market value of $814M by the end of 2026, taking into account their current cash reserves of $175M. The incorporation of a 20% probability of approval for their FT819 drug in SLE and a 1.5% terminal growth rate contribute to the overall positive outlook. While risks such as potential safety concerns and regulatory backlash exist, positive preliminary results from a Phase 1 trial evaluating their MICA/B show potential for anti-tumor activity, with a significant reduction in target lesions and tumor biomarker observed. Furthermore, their FT836 combination therapy is well-tolerated with no severe side effects observed.
Bears say
Fate Therapeutics is projected to have a market value of $826M in 2025 based on a discounted cash flow valuation, which takes into account the company's cash and investments. However, there is a high level of uncertainty surrounding the success of their leading product candidate, FT819, which has only a 20% probability of approval for SLE. The company also faces potential risks such as safety concerns and potential dilution.
This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares